Publicaciones en colaboración con investigadores/as de Institució Catalana de Recerca i Estudis Avançats (26)

2023

  1. Chromatin insulation orchestrates matrix metalloproteinase gene cluster expression reprogramming in aggressive breast cancer tumors

    Molecular Cancer, Vol. 22, Núm. 1

  2. Evaluation of triple negative breast cancer with heterogeneous immune infiltration

    Frontiers in Immunology, Vol. 14

2022

  1. Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer

    Cancer research, Vol. 82, Núm. 24, pp. 4670-4679

2021

  1. Epstein–Barr Virus+ B Cells in Breast Cancer Immune Response: A Case Report

    Frontiers in Immunology, Vol. 12

  2. PI3K activation promotes resistance to eribulin in HER2-negative breast cancer

    British Journal of Cancer, Vol. 124, Núm. 9, pp. 1581-1591

2020

  1. Enhancing global access to cancer medicines

    CA Cancer Journal for Clinicians, Vol. 70, Núm. 2, pp. 105-124

  2. The second generation antibody-drug conjugate syd985 overcomes resistances to T-DM1

    Cancers, Vol. 12, Núm. 3

2019

  1. The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer

    Cell Reports, Vol. 27, Núm. 9, pp. 2690-2708.e10

2018

  1. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER + breast cancer

    Nature Cell Biology, Vol. 20, Núm. 2, pp. 211-221

  2. Erratum to: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer (Nature Cell Biology, (2018), 20, 2, (211-221), 10.1038/s41556-017-0021-z)

    Nature Cell Biology

  3. Extracellular HMGA1 promotes tumor invasion and metastasis in triple-negative breast cancer

    Clinical Cancer Research, Vol. 24, Núm. 24, pp. 6367-6382

  4. Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases

    Oncotarget, Vol. 9, Núm. 29, pp. 20617-20630

  5. P95HER2–T cell bispecific antibody for breast cancer treatment

    Science Translational Medicine, Vol. 10, Núm. 461

  6. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1203-1210

2017

  1. Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer

    Cancer Research, Vol. 77, Núm. 9, pp. 2213-2221

  2. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

    Oncogene, Vol. 36, Núm. 19, pp. 2737-2749

2016

  1. High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy

    Molecular Oncology, Vol. 10, Núm. 1, pp. 138-147

  2. Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts

    Oncotarget, Vol. 7, Núm. 42, pp. 67956-67965

2015

  1. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

    Nature Communications, Vol. 6

  2. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab

    Clinical Cancer Research, Vol. 21, Núm. 3, pp. 569-576